Clinical Trial Detail

NCT ID NCT01599754
Title Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors SFJ Pharmaceuticals, Inc.
Indications

clear cell renal cell carcinoma

Therapies

Axitinib

Age Groups: adult

No variant requirements are available.